A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
Phase 1/2
Terminated
NCT05491317
| Condition | Non-CNS Tumor |
|---|
| Phase | Phase 1/2 |
|---|
| Sponsor | Genmab |
|---|
| Status | Terminated |
|---|
| Enrollment | 13 participants |
|---|
| Interventions | GEN1042, Pembrolizumab, Radiotherapy |
|---|
| Start date | Mar 8, 2023 |
|---|
| Completion date | Aug 11, 2025 |
|---|
| Results posted | Jul 2, 2026 |
|---|
Summary
The main purpose is to assess the safety and clinical activity of GEN1042 in combination with radiotherapy or GEN1042 in combination with radiotherapy and pembrolizumab as a treatment option for participants with metastatic solid tumors.
Number of Participants With Dose Limiting Toxicities (DLTs)
21 days · Participants
| Part 1 Cohort 1: 27Gy Stereotactic Body Radiotherapy (SBRT) + GEN1042 | 0 Participants |
|---|
| Part 1 Cohort 2: 27Gy SBRT + GEN1042 + Pembrolizumab | 0 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.